2 results
Approved WMORecruiting
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…
Approved WMORecruiting
The primary (performance) objective of the study is to assess the feasibility to treat repair type II endoleaks with ANEUFIX successfully, which is called *technical success*.The secondary objective of the study is to assess the clinical success…